{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:40:48Z","timestamp":1770532848660,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010318","name":"Landelijke Stichting voor Blinden en Slechtzienden","doi-asserted-by":"publisher","award":["2019-14"],"award-info":[{"award-number":["2019-14"]}],"id":[{"id":"10.13039\/501100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["648268"],"award-info":[{"award-number":["648268"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010321","name":"Oogfonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010372","name":"Rotterdamse Stichting Blindenbelangen","doi-asserted-by":"publisher","award":["20190034"],"award-info":[{"award-number":["20190034"]}],"id":[{"id":"10.13039\/501100010372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010378","name":"Stichting Wetenschappelijk Onderzoek Oogziekenhuis","doi-asserted-by":"publisher","award":["2019S06"],"award-info":[{"award-number":["2019S06"]}],"id":[{"id":"10.13039\/501100010378","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["91815655"],"award-info":[{"award-number":["91815655"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010302","name":"Algemene Nederlandse Vereniging ter voorkoming van Blindheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.oret.2023.06.025","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T02:22:00Z","timestamp":1688782920000},"page":"1010-1016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence and Risk Factors of Second Eye Involvement in Myopic Macular Neovascularization"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-6731","authenticated-orcid":false,"given":"Monica","family":"Ravenstijn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline C.W.","family":"Klaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Yzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2023.06.025_bib1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","article-title":"Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia","volume":"134","author":"Tideman","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2023.06.025_bib3","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.025_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00417-004-0960-5","article-title":"Characteristics of patients with a favorable natural course of myopic choroidal neovascularization","volume":"243","author":"Hayashi","year":"2005","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib6","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.025_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/IAE.0000000000002164","article-title":"Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia","volume":"39","author":"Onishi","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.025_bib8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/IAE.0000000000001313","article-title":"Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia","volume":"37","author":"Kasahara","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.025_bib9","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1097\/IAE.0000000000000632","article-title":"Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome","volume":"35","author":"Ruiz-Moreno","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.025_bib10","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.025_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000458160","article-title":"Improved visual outcome and low recurrence with early treatment with intravitreal anti-vascular endothelial growth factor in myopic choroidal neovascularization","volume":"237","author":"Moon","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2023.06.025_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/IAE.0000000000003675","article-title":"Long-term treatment outcomes after bevacizumab therapy for macular neovascularization in White patients with high myopia","volume":"43","author":"Ravenstijn","year":"2023","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.025_bib13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.oret.2022.06.009","article-title":"Long-term incidence and risk factors of macular fibrosis, macular atrophy, and macular hole in eyes with myopic neovascularization","volume":"6","author":"Cicinelli","year":"2022","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.oret.2023.06.025_bib14","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/IAE.0000000000001436","article-title":"Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic choroidal neovascularization","volume":"37","author":"Iacono","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.025_bib15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","article-title":"International photographic classification and grading system for myopic maculopathy","volume":"159","author":"Ohno-Matsui","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/ph14101042","article-title":"Ten-year outcomes of intravitreal bevacizumab for myopic choroidal neovascularization: analysis of prognostic factors","volume":"14","author":"Mallone","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.oret.2023.06.025_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ajo.2012.11.021","article-title":"Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization","volume":"155","author":"Leveziel","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib17","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1097\/IAE.0000000000001858","article-title":"Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in East-Asian patients from the Radiance study","volume":"38","author":"Tan","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.025_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjophthalmol-2017-310411","article-title":"Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group","volume":"102","author":"Chhablani","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1161\/01.CIR.99.1.111","article-title":"Age-dependent impairment of angiogenesis","volume":"99","author":"Rivard","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.oret.2023.06.025_bib22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/bjo.2009.163535","article-title":"Choroidal filling delay in choroidal neovascularisation due to pathological myopia","volume":"94","author":"Wakabayashi","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaophthalmol.2021.5346","article-title":"Prevalence of myopic macular features in Dutch individuals of European ancestry with high myopia","volume":"140","author":"Haarman","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.025_bib24","doi-asserted-by":"crossref","first-page":"M89","DOI":"10.1167\/iovs.18-25965","article-title":"IMI \u2013 myopia genetics report","volume":"60","author":"Tedja","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653023003044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653023003044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:32:07Z","timestamp":1762853527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653023003044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2468653023003044"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2023.06.025","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and Risk Factors of Second Eye Involvement in Myopic Macular Neovascularization","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2023.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}